Epidemiological and economic impact of pandemic influenza in Chicago: Priorities for vaccine interventions

PLoS Computational Biology

Volumn 13, Issue 6, 2017, Pages

  Dorratoltaj, Nargesalsadat ^a   Marathe, Achla ^b   Lewis, Bryan L ^b   Swarup, Samarth ^b   Eubank, Stephen G ^a,b   Abbas, Kaja M ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECONOMIC AND SOCIAL EFFECTS; INVESTMENTS; PROFITABILITY; SENSITIVITY ANALYSIS;

2009 H1N1; AGE GROUPS; CHICAGO; ECONOMIC IMPACTS; INFLUENZA PANDEMICS; PANDEMIC INFLUENZA; RETURNS ON INVESTMENT; RISK GROUPS; VACCINE EFFICACIES; VACCINE SUPPLIES;

VACCINES;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; DISEASE TRANSMISSION; ECONOMIC ASPECT; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; ILLINOIS; INCIDENCE; INFANT; INFLUENZA VACCINATION; NEWBORN; POPULATION DISTRIBUTION; POPULATION DYNAMICS; SOCIAL BEHAVIOR; BIOLOGY; ECONOMICS; INFLUENZA, HUMAN; MIDDLE AGED; PANDEMICS; PRESCHOOL CHILD; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VACCINATION; YOUNG ADULT;

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; CHICAGO; CHILD; CHILD, PRESCHOOL; COMPUTATIONAL BIOLOGY; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; MODELS, STATISTICAL; PANDEMICS; VACCINATION; YOUNG ADULT;

EID: 85021728289     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1005521     Document Type: Article

References (56)

1. CDC—ACIP—Advisory Committee on Immunization Practices (ACIP) Home Page—Vaccines [Internet]. [cited 2015 Jul 3]. Available from: http://www.cdc.gov/vaccines/acip/
2. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA, Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza Season. MMWR Morb Mortal Wkly Rep. 2015Aug7;64(30):818–25. 26247435
3. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009Jul31;58(RR-8):1–52. 19644442
4. Meltzer MI, Cox NJ, Fukuda K, The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999Sep;5(5):659–71. doi: 10.3201/eid0505.990507 10511522
5. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med. 1994Dec15;121(12):947–52. 7978721
6. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA. 2000Oct4;284(13):1655–63. 11015795
7. Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED, Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med. 2002Aug20;137(4):225–31. 12186512
8. Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, et al. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States. PLoS One. 2011Jul29;6(7):e22308. doi: 10.1371/journal.pone.0022308 21829456
9. Meltzer MI, Neuzil KM, Griffin MR, Fukuda K, An economic analysis of annual influenza vaccination of children. Vaccine. 2005Jan11;23(8):1004–14. doi: 10.1016/j.vaccine.2004.07.040 15620473
10. Borse RH, Shrestha SS, Fiore AE, Atkins CY, Singleton JA, Furlow C, et al. Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009–2010. Emerg Infect Dis. 2013Mar;19(3):439–48. doi: 10.3201/eid1903.120394 23622679
11. Kostova D, Reed C, Finelli L, Cheng P-Y, Gargiullo PM, Shay DK, et al. Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005–2011. PLoS One. 2013Jun19;8(6):e66312. doi: 10.1371/journal.pone.0066312 23840439
12. Biggerstaff M, Reed C, Swerdlow DL, Gambhir M, Graitcer S, Finelli L, et al. Estimating the potential effects of a vaccine program against an emerging influenza pandemic—United States. Clin Infect Dis. 2015May1;60Suppl 1:S20–9.
13. Meltzer MI, Bridges CB, Economic analysis of influenza vaccination and treatment. Ann Intern Med. 2003Apr1;138(7):608; author reply 608–9. 12667038
14. Lee BY, Brown ST, Korch GW, Cooley PC, Zimmerman RK, Wheaton WD, et al. A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine. 2010Jul12;28(31):4875–9. doi: 10.1016/j.vaccine.2010.05.002 20483192
15. Medlock J, Galvani AP, Optimizing influenza vaccine distribution. Science. 2009Sep25;325(5948):1705–8. doi: 10.1126/science.1175570 19696313
16. Hodgson D, Baguelin M, van Leeuwen E, Panovska-Griffiths J, Ramsay M, Pebody R, et al. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness analysis. The Lancet Public Health. 2017Feb;2(2):e74–81. doi: 10.1016/S2468-2667(16)30044-5 28299371
17. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS, Strategies for mitigating an influenza pandemic. Nature. 2006;442(7101):448–52. doi: 10.1038/nature04795 16642006
18. Germann TC, Kadau K, Longini IM, Macken CA, Mitigation strategies for pandemic influenza in the United States. Proceedings of the National Academy of Sciences. 2006;103(15):5935–40.
19. Ciofi degli Atti ML, Merler S, Rizzo C, Ajelli M, Massari M, Manfredi P, et al. Mitigation measures for pandemic influenza in Italy: an individual based model considering different scenarios. PLoS One. 2008Mar12;3(3):e1790. doi: 10.1371/journal.pone.0001790 18335060
20. Prosser LA, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari N-AM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis. 2006Oct;12(10):1548–58. doi: 10.3201/eid1210.051015 17176570
21. Coleman MS, Fontanesi J, Meltzer MI, Shefer A, Fishbein DB, Bennett NM, et al. Estimating medical practice expenses from administering adult influenza vaccinations. Vaccine. 2005Jan4;23(7):915–23. doi: 10.1016/j.vaccine.2004.07.028 15603893
22. Peasah SK, Azziz-Baumgartner E, Breese J, Meltzer MI, Widdowson M- A, Influenza cost and cost-effectiveness studies globally—a review. Vaccine. 2013Nov4;31(46):5339–48. doi: 10.1016/j.vaccine.2013.09.013 24055351
23. Monto AS, Davenport FM, Napier JA, Francis T, JrEffect of vaccination of a school-age population upon the course of an A2-Hong Kong influenza epidemic. Bull World Health Organ. 1969;41(3):537–42. 5309469
24. Longini IM, JrKoopman JS, Monto AS, Fox JP, Estimating household and community transmission parameters for influenza. Am J Epidemiol. 1982May;115(5):736–51. 7081204
25. Longini IM, Halloran ME, Nizam A, Wolff M, Mendelman PM, Fast PE, et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine. 2000Mar17;18(18):1902–9. 10699339
26. King JC, JrBeckett D, Snyder J, Cummings GE, King BS, Magder LS, Direct and indirect impact of influenza vaccination of young children on school absenteeism. Vaccine. 2012Jan5;30(2):289–93. doi: 10.1016/j.vaccine.2011.10.097 22085547
27. Glezen WP, Gaglani MJ, Kozinetz CA, Piedra PA, Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis. 2010Dec1;202(11):1626–33. doi: 10.1086/657089 21028955
28. CDC-MMWR. 2009; Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5833a1.htm
29. Bureau USC. Census.gov. [cited 2016 May 1]; Available from: http://www.census.gov/
30. Beckman RJ, Baggerly KA, McKay MD, Creating synthetic baseline populations. Transp Res Part A: Policy Pract. 1996Nov;30(6):415–29.
31. Barrett CL, Bisset KR, Eubank SG, Feng X, Marathe MV. EpiSimdemics: An Efficient Algorithm for Simulating the Spread of Infectious Disease over Large Realistic Social Networks. In: Proceedings of the 2008 ACM/IEEE Conference on Supercomputing. Piscataway, NJ, USA: IEEE Press; 2008. p. 37:1–37:12. (SC ‘08).
32. Barrett C, Bisset K, Leidig J, Marathe A, Marathe M, Economic and social impact of influenza mitigation strategies by demographic class. Epidemics. 2011Mar;3(1):19–31. doi: 10.1016/j.epidem.2010.11.002 21339828
33. Bisset K, Marathe M, A cyber-environment to support pandemic planning and response. DOE SciDAC Magazine. 2009;
34. Jhung MA, Swerdlow D, Olsen SJ, Jernigan D, Biggerstaff M, Kamimoto L, et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis. 2011Jan1;52Suppl 1:S13–26.
35. Reed Carrie, Biggerstaff Matthew, Finelli Lyn, Koonin Lisa M., Beauvais Denise, Uzicanin Amra, et al. Novel Framework for Assessing Epidemiologic Effects of Influenza Epidemics and Pandemics. Emerging Infectious Disease journal. 2013;19(1):85.
36. Meltzer MI, Gambhir M, Atkins CY, Swerdlow DL, Standardizing scenarios to assess the need to respond to an influenza pandemic. Clin Infect Dis. 2015May1;60Suppl 1:S1–8.
37. Seasonal Influenza Vaccine Effectiveness, 2005–2016 | Health Professionals | Seasonal Influenza (Flu) [Internet]. [cited 2016 Apr 22]. Available from: http://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm
38. Yoo B- K, Szilagyi PG, Schaffer SJ, Humiston SG, Rand CM, Albertin CS, et al. Cost of universal influenza vaccination of children in pediatric practices. Pediatrics. 2009Dec;124Suppl 5:S499–506.
39. Carias C, Reed C, Kim IK, Foppa IM, Biggerstaff M, Meltzer MI, et al. Net Costs Due to Seasonal Influenza Vaccination—United States, 2005–2009. PLoS One. 2015Jul31;10(7):e0132922. doi: 10.1371/journal.pone.0132922 26230271
40. Molinari N-AM, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007Jun28;25(27):5086–96. doi: 10.1016/j.vaccine.2007.03.046 17544181
41. Zimmerman RK, Lauderdale DS, Tan SM, Wagener DK, Prevalence of high-risk indications for influenza vaccine varies by age, race, and income. Vaccine. 2010Sep7;28(39):6470–7. doi: 10.1016/j.vaccine.2010.07.037 20674882
42. Hall JL, Katz BZ, Cost of influenza hospitalization at a tertiary care children’s hospital and its impact on the cost-benefit analysis of the recommendation for universal influenza immunization in children age 6 to 23 months. J Pediatr. 2005;147(6):807–11. doi: 10.1016/j.jpeds.2005.06.031 16356436
43. Fung IC-H, Meltzer MI, Borse RH. US Pandemic Influenza Vaccination Campaign 2009–10: a cost analysis of the US federal government’s funding appropriation. CDC/NCEZID/DPEI/SPSB Health Economics Modeling Unit White Paper [Internet]. 2013;(1). Available from: http://works.bepress.com/isaac_fung1/10/
44. SIBEL [Internet]. [cited 2016 Aug 29]. Available from: http://ndssl.vbi.vt.edu/apps/sibel/
45. R: The R Project for Statistical Computing [Internet]. [cited 2016 Aug 29]. Available from: https://www.r-project.org/
46. Marathe A, Lewis B, Barrett C, Chen J, Marathe M, Eubank S, et al. Comparing effectiveness of top-down and bottom-up strategies in containing influenza. PLoS One. 2011Sep22;6(9):e25149. doi: 10.1371/journal.pone.0025149 21966439
47. Halloran ME, Ferguson NM, Eubank S, Longini IM, JrCummings DAT, Lewis B, et al. Modeling targeted layered containment of an influenza pandemic in the United States. Proc Natl Acad Sci U S A. 2008Mar25;105(12):4639–44. doi: 10.1073/pnas.0706849105 18332436
48. Dover DC, Kirwin EM, Hernandez-Ceron N, Nelson KA, Pandemic Risk Assessment Model (PRAM): a mathematical modeling approach to pandemic influenza planning. Epidemiol Infect. 2016Aug22;1–12.
49. Yu Z, Liu J, Wang X, Zhu X, Wang D, Han G, Efficient Vaccine Distribution Based on a Hybrid Compartmental Model. PLoS One. 2016May27;11(5):e0155416. doi: 10.1371/journal.pone.0155416 27233015
50. Patrozou E, Mermel LA, Does influenza transmission occur from asymptomatic infection or prior to symptom onset?Public Health Rep. 2009Mar;124(2):193–6. doi: 10.1177/003335490912400205 19320359
51. Wu JT, Riley S, Fraser C, Leung GM, Reducing the impact of the next influenza pandemic using household-based public health interventions. PLoS Med. 2006Sep;3(9):e361. doi: 10.1371/journal.pmed.0030361 16881729
52. Elveback LR, Fox JP, Ackerman E, Langworthy A, Boyd M, Gatewood L, An influenza simulation model for immunization studies. Am J Epidemiol. 1976Feb;103(2):152–65. 814808
53. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008Apr1;167(7):775–85. doi: 10.1093/aje/kwm375 18230677
54. Cori A, Valleron AJ, Carrat F, Scalia Tomba G, Thomas G, Boëlle PY, Estimating influenza latency and infectious period durations using viral excretion data. Epidemics. 2012Aug;4(3):132–8. doi: 10.1016/j.epidem.2012.06.001 22939310
55. Clinical Signs and Symptoms of Influenza | Health Professionals | Seasonal Influenza (Flu) [Internet]. [cited 2017 Feb 15]. Available from: https://www.cdc.gov/flu/professionals/acip/clinical.htm
56. Vink MA, Bootsma MCJ, Wallinga J, Serial intervals of respiratory infectious diseases: a systematic review and analysis. Am J Epidemiol. 2014Nov1;180(9):865–75. doi: 10.1093/aje/kwu209 25294601